Re: Urgent-Does anybody know about the Lentz Treatment?

August 15, 2003

Why don't you contact Ralph Moss or Burton Goldberg (Alternative

medicine magazine). I'm sure that either one of them may be able to

help you locate him quickly.

http://www.ralphmoss.com/troph.html

1994

Recent discoveries by scientists worlds apart have unexpectedly

breathed new life into an old view: the trophoblastic theory of

cancer.The first scientist is Valentin I. Govallo, MD, PhD, director

of the Laboratory of Immunology in Moscow. Govallo is the author of

290 scientific articles and 20 books, including The Immunology of

Pregnancy and Cancer (1993).

The second is M. Rigdon Lentz, MD, PhD, currently the chief of

hematology and oncology at the Comprehensive Cancer Center of

Valdosta, GA. Before this year, neither scientist knew of each

other's work. ........

.........According to Govallo, the reason for the failure was that the

tumor itself was hindering the activity of the immune system,

emitting certain " blocking factors. " This was a theory first proposed

by orthodox scientists in the late 1960s. (It is also an integral

part of Dr. Lawrence Burton's Immunoaugmentative Therapy, or IAT,

practiced in the Bahamas since the late 1970s.) .........

Dr. M. Rigdon Lentz has also spent two decades investigating the

ability of cancer to turn off an otherwise-normal immune system.

Attempting to physically remove blocking factors, he custom built a

machine that filters them out of the cancer patient's bloodstream,

using a technique called UltraPheresis (comparable to kidney

dialysis). In the late 1980s, Lentz carried out FDA-supervised Phase

I and Phase II studies, removing plasma fractions with low molecular

weights from the blood. Unlike Govallo, who sees a few Russian

patients a month, Lentz is not currently treating patients with his

method, as the objective of the earlier trials was scientific

knowledge. Additional funding would be required to proceed with more

extensive Phase III studies.

In the prestigious Proceedings of the National Academy of Sciences,

Lentz and colleagues identified, purified, and characterized immune

system inhibitors found in the blood of cancer patients. These were

identified as receptors for tumor necrosis factor (TNF) (PNAS 87:8781-

8784, 1990; also, Cell 61:361-370, 1990). By producing this factor,

the tumor is apparently able to deactivate the body's otherwise

powerful immune response to foreign tissues. The discovery of

this " anti-TNF " is an exciting scientific finding, with implications

for the treatment of a number of different diseases.

Lentz's published results contain many revelations about the ultimate

power of the immune system, once it is deblocked, to destroy

tumors.One of the most startling facts is that the first three of

Lentz's terminally ill patients who died in the initial clinical

trial had tumor lysis syndrome: dead cancer cells and debris that can

overwhelm the liver and kidneys (J Biol Response Mod 8:511-527,

1989). Autopsies of these patients showed that " all measurable

disease " had been destroyed due to " massive hemorrhagic and

coagulative necrosis. " Lentz learned that one must proceed slowly in

harnessing such explosive anti-cancer reactions.

Patients receiving UltraPheresis also experienced intense, if

transient, pain in their primary tumor and metastases. There was also

fever, which Lentz brought down with the drug, acetaminophen

(Tylenol®).Sixteen patients were treated between June, 1985 and

April, 1986. As noted, three (18.7%) died after rapid tumor

breakdown. A general improvement in physical condition and sense of

well-being was seen in 65% of the cases, accompanied by improved

appetite & weight gain.

In 1942, these ideas were rediscovered by Ernst T. Krebs, Jr. and his

colleagues. In July, 1950, they published an article in the Medical

Record on " The Unitarian or Trophoblastic Thesis of Cancer. " Krebs

continues as director of the Beard Memorial Foundation of San

Francisco. His oft-stated belief is that " cancer is trophoblast in

spatial and temporal anomaly, hybridized with, and vascularized by,

hostal or somatic cells and in irreversible and fiercely malignant

antithesis to such " (Townsend Letter for Doctors, Feb.-March, 1993,

p. 175).

Krebs is also co-discover of Laetrile, and so the fate of the

trophoblastic theory became intertwined with the trials and

tribulations of that apricot kernel-derived chemical. A final blow

seemed to come in 1990, when a prominent laetrilist, Bradford,

announced that modern research had undermined the trophoblastic

thesis. " Say goodbye to an old friend, " he wrote in The Choice.In

this article, Bradford raised many technical objections to the

Beardian thesis. And indeed many questions need to be answered before

this theory can be accepted as fact. What is remarkable, however, is

how two scientists have now independently proclaimed their belief in

an updated version of that theory, arriving at their conclusions

without studying Beard's seminal work.

###

Ralph W. Moss, Ph.D. is the author of eight books and three

documentaries on cancer-related topics. He is an advisor on

alternative cancer treatments to the National Institutes of Health,

Columbia University, and the University of Texas. He researches and

writes individualized " Healing Choices " reports for people with

cancer. For information on Healing Choices, you can contact

coordinator Anne Beattie @ 144 St. 's Place, Brooklyn, NY 11217;

Phone 718-636-4433; Fax 718-636-0186.

> Hello,

>

> I am urgently trying to get a hold of Dr M Rigdon Lentz who is

> currently running the Ultrapheresis treatment in Mainz Germany.

>

> Please only send genuine leads. Thank you.

>

> Regards,

>

> Mrs E M Salecker

August 15, 2003